Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Spendlove

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
QJM : Monthly Journal of the Association of Physicians|September 1, 1996
Cancer vaccinesL G Durrant, I Spendlove
Expert Opinion on Emerging Drugs|December 10, 2003
Cancer vaccines entering Phase III clinical trialsL G Durrant, I Spendlove
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunization against tumor cell surface complement-regulatory proteinsL G Durrant, I Spendlove
Tissue Antigens|November 26, 2002
The role of CD55 in protecting the tumour environment from complement attackJ Morgan, I Spendlove, L G Durrant
Clinical and Experimental Immunology|January 13, 2012
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapyL G Durrant, P Noble, I Spendlove
Cancer Research|May 27, 1999
Decay accelerating factor (CD55): a target for cancer vaccines?I Spendlove, L Li, J Carmichael, et al.
British Journal of Cancer|January 5, 2001
CD55 is over-expressed in the tumour environmentL Li, I Spendlove, J Morgan, et al.
International Journal of Cancer|December 10, 1999
105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responsesL G Durrant, D J Buckley, R A Robins, et al.
Hybridoma|February 1, 1997
Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunityL G Durrant, D J Buckley, I Spendlove, et al.
The Journal of Pathology|January 1, 1992
alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human diseaseJ Lowe, H McDermott, I Pike, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
QJM : Monthly Journal of the Association of Physicians|September 1, 1996
Cancer vaccinesL G Durrant, I Spendlove
Expert Opinion on Emerging Drugs|December 10, 2003
Cancer vaccines entering Phase III clinical trialsL G Durrant, I Spendlove
Current Opinion in Investigational Drugs (London, England : 2000)|January 5, 2002
Immunization against tumor cell surface complement-regulatory proteinsL G Durrant, I Spendlove
Tissue Antigens|November 26, 2002
The role of CD55 in protecting the tumour environment from complement attackJ Morgan, I Spendlove, L G Durrant
Clinical and Experimental Immunology|January 13, 2012
Immunology in the clinic review series; focus on cancer: glycolipids as targets for tumour immunotherapyL G Durrant, P Noble, I Spendlove
Cancer Research|May 27, 1999
Decay accelerating factor (CD55): a target for cancer vaccines?I Spendlove, L Li, J Carmichael, et al.
British Journal of Cancer|January 5, 2001
CD55 is over-expressed in the tumour environmentL Li, I Spendlove, J Morgan, et al.
International Journal of Cancer|December 10, 1999
105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responsesL G Durrant, D J Buckley, R A Robins, et al.
Hybridoma|February 1, 1997
Low doses of 105AD7 cancer vaccine preferentially stimulate anti-tumor T-cell immunityL G Durrant, D J Buckley, I Spendlove, et al.
The Journal of Pathology|January 1, 1992
alpha B crystallin expression in non-lenticular tissues and selective presence in ubiquitinated inclusion bodies in human diseaseJ Lowe, H McDermott, I Pike, et al.
Pageof 3